Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 4;14:1251603. doi: 10.3389/fimmu.2023.1251603

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Nguyen, Tran, Nguyen, Nguyen, Pham, Nguyen, Tran, Nguyen, Tran, Pham, Le, Phan, Giang, Nguyen and Tran

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Validation of neoantigens in silico identified from the modified workflow by ELISpot assays on four CRC patients. (A) A schematic diagram illustrates the procedural steps of neoantigen prioritization and the ELISpot assay. (B) The number of each type of neoantigens identified from each CRC patient. (C) The fold change in IFN-γ spots, relative to the wildtype peptides, for 40 long peptides. Note: only the mutants that result in a positive value in ELISpot are depicted with their corresponding amino acid change. (D) The percentage of IFN-γ expressing CD4+ T cells induced by indicated long peptides. Note: these long peptides induce a more than 2-fold change in IFN-γ spots as observed in the ELISpot assay. (E) The percentage of IFN-γ expressing CD8+ T cells induced by indicated long peptides.